Duopharma Biotech Berhad

KLSE:DPHARMA Stock Report

Market Cap: RM 1.2b

Duopharma Biotech Berhad Past Earnings Performance

Past criteria checks 2/6

Duopharma Biotech Berhad has been growing earnings at an average annual rate of 0.01%, while the Pharmaceuticals industry saw earnings growing at 11.6% annually. Revenues have been growing at an average rate of 6.4% per year. Duopharma Biotech Berhad's return on equity is 8.1%, and it has net margins of 7.1%.

Key information

0.009%

Earnings growth rate

-1.4%

EPS growth rate

Pharmaceuticals Industry Growth7.7%
Revenue growth rate6.4%
Return on equity8.1%
Net Margin7.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17
Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21
These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18
Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07
Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28
Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27
Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26
We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25
Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20
Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22
Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13
Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 14
A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Feb 12
Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Jan 28
Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Revenue & Expenses Breakdown

How Duopharma Biotech Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KLSE:DPHARMA Revenue, expenses and earnings (MYR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24788561920
30 Jun 24748491860
31 Mar 24697451830
31 Dec 23705531870
30 Sep 23689611890
30 Jun 23697691900
31 Mar 23711721900
31 Dec 22697701860
30 Sep 22690691800
30 Jun 22685691760
31 Mar 22659681710
31 Dec 21639661660
30 Sep 21628661620
30 Jun 21590631540
31 Mar 21578631490
31 Dec 20570591500
30 Sep 20574541530
30 Jun 20583551550
31 Mar 20585541600
31 Dec 19576551550
30 Sep 19554581460
30 Jun 19537551400
31 Mar 19516511380
31 Dec 18499481370
30 Sep 18495451330
30 Jun 18485441370
31 Mar 18478441350
31 Dec 17468421290
30 Sep 17430391290
30 Jun 17395341230
31 Mar 17357291150
31 Dec 16313271090
30 Sep 16327311080
30 Jun 16326331080
31 Mar 1630435960
31 Dec 1527036780
30 Sep 1523234600
30 Jun 1519834410
31 Mar 1518236330
31 Dec 1417735330
30 Sep 1417233330
30 Jun 1416831310
31 Mar 1416534320
31 Dec 1316232300

Quality Earnings: DPHARMA has high quality earnings.

Growing Profit Margin: DPHARMA's current net profit margins (7.1%) are lower than last year (8.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DPHARMA's earnings have grown by 0.01% per year over the past 5 years.

Accelerating Growth: DPHARMA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DPHARMA had negative earnings growth (-8.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-16.4%).

Return on Equity

High ROE: DPHARMA's Return on Equity (8.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 21:10
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Duopharma Biotech Berhad is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Khir GohAmInvestment Bank Berhad
Kok CheeAmInvestment Bank Berhad
Hsien Jin LamCGS International